February 7, 2020 / 6:37 AM / 18 days ago

BRIEF-Roche Gives Update On Tecentriq For Treatment Of Liver Cancer

Feb 7 (Reuters) - Roche Holding AG:

* ROCHE TO PRESENT NEW DATA ON TECENTRIQ IN COMBINATION WITH AVASTIN THAT SHOWS IMPROVEMENT IN OVERALL SURVIVAL FOR CHINESE PATIENTS WITH THE MOST COMMON FORM OF LIVER CANCER

* OVERALL SURVIVAL OUTCOMES FOR CHINESE PATIENTS TREATED WITH THE COMBINATION OF TECENTRIQ AND AVASTIN ARE CONSISTENT WITH THE OVERALL SURVIVAL REPORTED FOR THE GLOBAL PATIENT POPULATION OF THE IMBRAVE150 STUDY

* IMBRAVE150 IS THE FIRST CANCER IMMUNOTHERAPY STUDY TO SHOW AN IMPROVEMENT IN OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL IN PEOPLE WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA COMPARED WITH SORAFENIB Source text for Eikon: Further company coverage: (Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below